Another Argument for Free Market Drugs: Limits on Supply of Patients for Clinical Trials

In a very interesting column in the Wall Street Journal, Peter Bach and Mark Trusheim argue that biosimilar drugs have been ineffective in providing effective competition for biological drug. The gist of the argument is that the testing process required for a biosimilar is lengthy and expensive.

Furthermore, this testing requires a large number of patients for clinical trials.This can lead to the perverse situation where testing for a biosimilar could be pulling potential patients from being...